Articles

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Federico II University of Naples, Naples, Italy and AORN Moscati, Avellino
King's College Hospital-NHS Foundation Trust, NIHR/Wellcome King’s Clinical Research Facility, London, UK and King’s College London, London
Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul
Cleveland Clinic, Cleveland, OH
Core Research Laboratory, Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Firenze, Italy; Azienda Ospedaliera-Universitaria Careggi, Firenze
Johns Hopkins University School of Medicine, Baltimore, MD
Achillion, Inc., A Subsidiary of Alexion Pharmaceuticals, Inc., New Haven, CT, USA; Alexion Pharmaceuticals, New Haven CT
Achillion Inc., A Subsidiary of Alexion Pharmaceuticals, Inc., Blue Bell, PA
University of Auckland, Auckland
Haematologica Early view Oct 29, 2020 https://doi.org/10.3324/haematol.2020.261826